Catalyst Biosciences is Hosting KOL Meeting on Subcutaneous Factor-VIIa Marzeptacog Alfa (Activated) in Bleeding Disorders Patients on 15 August

Catalyst Biosciences, Inc. (NASDAQ: CBIO), announced today that it will be hosting a Key Opinion Leader (KOL) Subcutaneous Factor VIIa (FVIIa) next-generation marzeptacog alfa (enabled) (MarzAA) meeting on Thursday, August 15 in New York City. The event is planned for 12:00-2:00 p.m. EDT and webcast at the same time.

KOLs Robert Klamroth, M.D., Ph.D., Vivantes Hospital, Berlin, Germany, and Steven W. Pipe, M.D., C. S. Mott Children’s Hospital, Ann Arbor, MI. Drs will present the event. Klamroth and Pipe will address the present therapy landscape and unmet medical requirements to treat people with haemophilia A and B, factor VII deficiency and other bleeding disorders, and the need for subcutaneous therapies to treat bleeding.

The senior management team of Catalyst Biosciences will provide updates on MarzAA’s clinical development, including a review of the recently completed P2 test in inhibitor patients, an overview of market opportunities for MarzAA, preclinical efficacy data supporting subcutaneous treatment of bleeding episodes, and MarzAA preclinical safety data in combination with Hemlibra ®.

Robert Klamroth, M.D., Ph.D., specializes in diseases of coagulation and internal medicine. He has been the director and deceased of the Department of Internal Medicine (Angiology and Hemostasis, Haemophilia Center and Coagulation Clinic) at Vivantes Hospital Friedrichshain, Berlin, Germany since 2014. Dr Klamroth obtained his medical degree in 1994 and his PhD in 1996 from Free University, Berlin, Germany, and later became an academic assistant at the University Medical Center’s Clinic for Internal Medicine and Complementary Medicine. He was named Assistant Medical Director at the Clinic for Angiology and Haemostasis in 2001, the Haemophilia Center and Coagulation Clinic, and Director of the Haemophilia Treatment Center, Vivantes Hospital’s Department of Coagulation Disorders. Dr Klamroth is a member of the Executive Committee of the European Association of Haemophilia and Allied Disorders (EAHAD) and has membership in the fields of angelology, thrombosis and haemostasis in numerous domestic and regional communities. He also acts as a speaker for the German Thrombosis and Haemostasis Society’s haemophilia committee.